NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/14/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization15.14 mln
Float30.83 mln
Earnings Date05/18/2026
Piotroski F-Score
3
/ 9
Below average
Relative Strength
95
/ 100
Top performer
Debt / Equity
0.00
Debt-free
ROE
-1,294
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
GT Biopharma is a San Francisco-based company focused on developing cancer and autoimmune disease treatments. Its work centers on a proprietary technology designed to direct the body's natural killer cells toward diseased cells, with several drug candidates currently moving through early-stage clinical trials targeting blood cancers, solid tumors, and conditions such as lupus. Originally founded in 1965 under the name OXIS International, the company rebranded in 2017 and continues to advance its pipeline toward potential commercialization.
